Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Ospedali Riuniti di Bergamo |
---|---|
Information provided by: | Ospedali Riuniti di Bergamo |
ClinicalTrials.gov Identifier: | NCT00433056 |
LOTTI study Centers
This a multicenter, multinational study.
Clinical phase: III
Objectives
The primary objective is to compare efficacy and safety of continuing a conventional HAART in chronically infected HIV patients with a therapeutic strategy based on long term, immunologically driven treatment interruptions.
Secondary objectives are:
Number of Patients: A total of 320 patients.
Study design:
Controlled, Randomized, Open study The study will last 5 years
Treatment arms:
Patients will be randomized in a ratio 1:1 to one of the two treatment arms Control group continuing the ongoing therapy STI group performing long term CD4 guided structured treatment interruptions In the STI arm patients will stay off therapy until their CD4 count will drop < 350 cells/mcL (one measurement will be considered sufficient). At that time point patients will resume the HAART regimen they were assuming before STI and will continue HAART until they CD4 count will raise > 600 cells/mcL (at least 2 consecutive measurements 2 months apart) and their HIV-RNA will drop below the detection limit of 50 copies/ml (one measurement will be considered sufficient). When both the CD4 count and the viral load will be within these pre-set values they will stop therapy again. There is no limit to the number of interruptions and re-start cycles during the study period
End points:
The primary end-point for the evaluation of the main objective of the study will be clinical. The primary outcome measure will be based on the occurrence of a clinical end-point defined as: disease progression (occurrence of any AIDS defining event), death for any cause or the occurrence of clinical events requiring hospital admission
The secondary objectives of the study will be evaluated on the basis of:
Statistics:
The study is powered to evaluate equivalence between the two strategies under the assumption that, in the control arm, the primary end-point would be observed in a proportion of subjects < 7% and that the same proportion in the STI arm would not exceed 10% with a maximum allowed 95%CI of 12%. 320 patients will be needed for alfa = 5% and 1-beta = 80%. The primary analysis will be made according to the intention-to-treat approach and therefore no correction for eventual drop outs is needed. In addition, a secondary per-protocol analysis will be performed.
Condition | Intervention | Phase |
---|---|---|
HIV Infections AIDS |
Other: STI Drug: stable HAART |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Strategic, Long Term, Immunologically Driven Treatment Interruptions in Patients on Effective HAART: A Controlled, Randomized Study |
Estimated Enrollment: | 320 |
Study Start Date: | January 2004 |
Arms | Assigned Interventions |
---|---|
1: Experimental
STI
|
Other: STI
CD4 guided treatment interruption
|
2: Active Comparator
stable HAART, Any registered regimen containing NRTIs (AZT or D4T or 3TC or TDF or DDI), NNRTIs (EFV or NVP) or PIs (RTV-boosted ATV; IDV; LPV, fosAPV, SQV; unboosted ATV or NFV)is allowed according to international guidelines
|
Drug: stable HAART
continuous therapy
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | LOTTI |
Study First Received: | February 7, 2007 |
Last Updated: | April 24, 2008 |
ClinicalTrials.gov Identifier: | NCT00433056 History of Changes |
Health Authority: | Italy: Istituto Superiore di sanità |
STI HIV CD4 HIV-RNA HAART |
Virus Diseases Sexually Transmitted Diseases, Viral HIV Infections Sexually Transmitted Diseases |
Acquired Immunodeficiency Syndrome Retroviridae Infections Immunologic Deficiency Syndromes |
Virus Diseases Sexually Transmitted Diseases, Viral RNA Virus Infections Slow Virus Diseases Immune System Diseases HIV Infections |
Sexually Transmitted Diseases Acquired Immunodeficiency Syndrome Lentivirus Infections Infection Retroviridae Infections Immunologic Deficiency Syndromes |